Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCND3 | P30281 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12106578 | 0.87 | RAB9A (0.46) | CHEK1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL1300899 | 0.86 | RAB9A (0.49) | CHEK1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL4096515 | 0.82 | FGFR1 (0.54) | CHEK1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL18873552 | 0.77 | PDE4D (0.61) | RAB9ANPC1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL28348674 | 0.75 | KDM4E (0.67) | RAB9ANPC1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL13849191 | 0.74 | FLT3 (0.65) | HSD17B10KDM4E | |
| SCHEMBL13849263 | 0.74 | FLT3 (0.56) | CHEK1FGFR1FLT1POLBBRD4 | |
| SCHEMBL13849202 | 0.74 | FLT3 (0.61) | CHEK1 | |
| SCHEMBL5951954 | 0.74 | PDE4D (0.50) | RAB9ANPC1KMT2ASMN1; SMN2AURKA | |
| SCHEMBL21240753 | 0.73 | DAGLA (0.54) | RAB9AKMT2ASMN1; SMN2MAPK1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1891048-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | Vernalis (R&D) Limited (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006134318-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | CHEK1 2/4885RAB9A 1256/4885NPC1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.